These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35569010)

  • 21. Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.
    Borysowski J; Górski A
    Eur J Intern Med; 2019 Jul; 65():12-16. PubMed ID: 31036436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implementation of 21st Century Cures Act Expanded Access Policies Requirements.
    Kang S; Chang S; Ross JS; Miller JE
    Clin Pharmacol Ther; 2021 Dec; 110(6):1579-1584. PubMed ID: 34431083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient advocacy organizations' information for patients on pre-approval access to investigational treatments.
    Folkers KM; Leone S; Caplan A
    BMC Res Notes; 2019 Oct; 12(1):706. PubMed ID: 31661023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma].
    Marschner N
    Onkologie; 2010; 33 Suppl 1():12-4. PubMed ID: 20164671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program.
    Feit NZ; Goldman DA; Smith E; Deighan J; Iasonos A; Zivanovic O; Hyman DM
    JAMA Oncol; 2019 Apr; 5(4):570-572. PubMed ID: 30816938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-patient expanded access: A primer for pharmacists.
    Smith AJF; Redic KA
    Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compassionate use of drugs and medical devices in the United States, the European Union and Japan.
    Tsuyuki K; Yano K; Watanabe N; Aruga A; Yamato M
    Regen Ther; 2016 Jun; 4():18-26. PubMed ID: 31245484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Access to 'investigational' cancer drugs: perspective of a trainee.
    Kuo JC
    Intern Med J; 2015 Feb; 45(2):235. PubMed ID: 25650544
    [No Abstract]   [Full Text] [Related]  

  • 30. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework.
    Mehrotra N; Manchikanti P
    Med Law Rev; 2024 Feb; 32(1):20-41. PubMed ID: 37616571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
    Jacquet E; Kerouani-Lafaye G; Grude F; Goncalves S; Lorence A; Turcry F; Brunel L; Belgodere L; Monard A; Guyader G; Boudali L; Albin N
    Eur J Cancer; 2021 May; 149():82-90. PubMed ID: 33838392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Which efficacy trials for drugs for rare diseases?].
    Traversa G; Trotta F
    Epidemiol Prev; 2017; 41(5-6):318-319. PubMed ID: 29119773
    [No Abstract]   [Full Text] [Related]  

  • 35. [Compassionate use of non-approved medicinal products. Legal basis and guidelines].
    Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):439-43. PubMed ID: 19343282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Federal Right to Try Act of 2017-A Wrong Turn for Access to Investigational Drugs and the Path Forward.
    Bateman-House A; Robertson CT
    JAMA Intern Med; 2018 Mar; 178(3):321-322. PubMed ID: 29356821
    [No Abstract]   [Full Text] [Related]  

  • 37. Japan works to shorten "drug lag," boost trials of new drugs.
    Sinha G
    J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160
    [No Abstract]   [Full Text] [Related]  

  • 38. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan.
    Imamura CK; Takebe N; Nakamura S; Saya H; Ueno NT
    Nat Rev Clin Oncol; 2010 Mar; 7(3):127-8. PubMed ID: 20190792
    [No Abstract]   [Full Text] [Related]  

  • 40. Physician perspectives on compassionate use in pediatric oncology.
    Moerdler S; Zhang L; Gerasimov E; Zhu C; Wolinsky T; Roth M; Goodman N; Weiser DA
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27545. PubMed ID: 30408307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.